use U80. Both doctors and patients would resist doubling the injection volume, which would result if U80 was abandoned and U40 became standard. If we standardised on U80 we would be the only country in the world likely to do so, and old syringes and obsolete instruction leaflets would continue to cause confusion. U100 has already been adopted by the United States, Canada, and Austrialia, with New Zealand following shortly.
After seeing the results from clinical trials at several British centres, considering the experience of other countries, and debating the problems and hazards of change, the British Diabetic Association determined to seek standardisation of insulin strength at U100. Doctors who belong to the BDA voted unanimously for this change. At a meeting in Aberdeen in September 1980 they showed their disquiet that the change was proceeding so slowly. Other professional bodies have also formally welcomed the principle of U100 as the sole insulin strength: the Royal Colleges of Physicians With U100 insulin will come a new British Standard U100 insulin syringe, graduated and numbered directly in units of insulin. There will be two sizes-one for injections of up to 50 units, the other up to 100 units and both marked in units. The 50-unit syringe will allow even small doses to be measured and delivered accurately. These syringes have already been shown to be suitable for small children. Plastic syringes for U100 are already available and though in most areas patients still have to buy them, they are very cheap if used repeatedly, safe,' and recommended by most clinics and by the BDA. We hope that the change to U100 will come in 1982. The change-over will probably be largely carried out at diabetic clinics, though general practitioners and all other relevant agencies will be affected. A carefully prepared programme of information and organisation has already been started.
We believe that the great majority of doctors accept that the interest and safety of diabetic patients is best served by this change. Legitimate doubts and hesitations have been expressed-particularly a reluctance to change the practice for a patient already well established for whom there may be no obvious advantage. The whole-hearted support of the medical profession is vital so that the demand for U40 and U80 ends and these strengths are withdrawn. Initiating, organising, and implementing the change to U100 are in the hands of the doctors, for there is no legislative process in Britain by which the withdrawal can be effected. We solicit their support earnestly but confidently. Under the section "measurable lesions" the UICC report states, "Ideally, all lesions should be measured at each assessment. When multiple lesions are present this may not be possible and under such circumstances a representative number of eight or more lesions may be selected for measurement." The measurement recommended by the UICC report was "the sum of the products of the diameters (one being the longest and the other the longest perpendicular to it) of each individual lesion, or those selected for study." In those cases where two measurements are not possible the diameter or sums of diameters should be used.
The UICC report did not make any specific recommendations about the duration of response that qualified the patient to be classified in this category. The statement reads, "In a patient who has objective regression, this is to be dated from the start of therapy until either new lesions appear or any existing lesion increases by 25% or more above its smallest size recorded. It is essential to categorise a patient as having a regression at a stated time. It is also essential that all baseline studies should be repeated at this time." Despite no specific recommendation by the UICC, the minimum response duration is now generally accepted as four weeks. Although this seems pathetically short, let us accept the criterion and examine the remaining elements in the partial response.
TUMOUR COMPOSITION
Before we can attempt to contemplate what a partial response of a tumour might mean in real terms we must consider the composition of that tumour. Human tumours contain normal as well as neoplastic cells. The former include endothelial cells, connective tissue elements -for instance, fibroblasts-and some normal cells of the type from which the tumour arose. Also included are red blood cells, polymorphonuclear leucocytes, lymphocytes, and macrophages, which may be present in considerable numbers in a necrotic neoplasm. The neoplastic tissue may be divided into three "functional" categories: dead cells, differentiating or end cells, and clonogenic cells. The differentiating and clonogenic cell components may both be subdivided into hypoxic and euoxic compartments, and hypoxic cells are less likely to be within the division cycle and undergoing active proliferation. The importance of any clonogenic cells arrested in a "Go" state owing to hypoxia or other undefined nutrient factors is that they may be relatively insensitive not only to radiation but also to chemotherapeutic attack owing to diffusion problems, and still retain the capacity to enter the division cycle if conditions become more favourable. Actively proliferating cells may be further subdivided into the four stages of the cell cycle-mitosis, GI, S-phase, and G2-and each of these phases may have different sensitivities to therapeutic agents. So far a total of no fewer than 24 different "compartments" have been defined that may be present even in the very simplified tumour model described above. A reduction in "size" of the tumour may be due to a decrease in any one, or any combination, of these compartments. MEASUREMENT 
PARAMETERS
In some rare tumours biochemical measurements performed on peripheral blood give an indication of the total tumour bulk. Perhaps the best examples are myeloma proteins3 and the human chorionic gonadotrophin of chorion carcinoma.4 In the most common tumours -carcinomas of the breast, bronchus, and bowel-no such reliable markers exist, and we have to depend on radiographs, isotope scans, fingers, and callipers to assess the size of the tumour. Measurements so obtained may be expressed as diameters, areas, or volumes.
Although the UICC recommendation is equivalent to an area assessment (the product of two diameters), the relationship between the 35 three parameters will be examined as there are reports that have used each of these for assessment. The volume of a sphere is related to the cube of the radius, the area of a circle is related to the square of the radius, and the diameter is directly related to the radius. If an assessment is being made on diameter a 50% reduction will reduce the area to 25% and the volume to 12-5%. When area is used as the assessment criterion a 50% reduction will reduce the volume to 36% and the diameter will be reduced to 71%. If volwne is used a 50% reduction reduces the diameter to 80% and the area to 64%. Clearly a report using volume for assessing partial response, even if it adheres rigorously to the criterion of a 50% reduction for the minimum interval of four weeks, is far less convincing than a similar report using diameter as the assessment criterion. In the latter case the volume is reduced to 12-5%.
GROWTH KINETIC CONSIDERATIONS
The net increase in volume of a tumour reflects the excess of cell production over cell loss from thetumour. Steel5 has defined a parameter, the cell loss factor (CLF), which is equal to the ratio of the rate of cell loss divided by the rate of cell production.
If a tumour is composed exclusively of tumour cells a CLF of unity represents the condition where cell loss from the tumour exactly equals cell production and the net growth increase is zero. A CLF greater than unity defines the condition where the tumour is shrinking, and a value of less than unity continuing growth. The few experimental data available indicate that the CLF for certain human tumours may be about 90% or greater during unperturbed growth.6
To obtain values for the CLF, however, we must know the overall growth rate and the rate of cell production. Breur, in a careful study,7 has shown that secondary disease in the lungs grows exponentially in the vast majority of tumours. The doubling time, however, ranged from under 10 days in the fastest-growing tumours to over 160 days in the slowest, and there was considerable variation not only within but also between histological types. These results agreed with those of Collins et al. 8 Determination of growth rate requires at least three observations, and to obtain reasonable accuracy the untreated patient probably needs to be observed for two tumour doublings. This is a four-fold volume increase, and to delay treatment long enough for the information to be acquired may be unethical in manypatients. Although the growth rate can be determined, the rate of cell production is notoriously difficult to obtain from human tumours9; thus the CLF is not likely to be a practicable aid to assessment within the foreseeable future. Nevertheless, it is useful conceptually. We regression criterion (product of two diameters) was employed and 7% if a 50% criterion was employed. When, however, the oncologist is measuring a deep-seated irregular mass through the musde guarding of an uncomfortable patient, the errors of his measurement will undoubtedly be far greater than that recorded under the structure of this study. Certainly under real life circumstances, a 25% regression must be considered meaningless, and even a 50% regression is questionable."
Conclusions
The title of this article poses the question of what "response" in cancer chemotherapy really means. If we exclude the minority groups in whom an increased span of useful life has been shown to occur and turn our attention to the problem of metastatic cancer of the breast, bowel, and bronchus the answer must be "Not very much." What is perhaps even worse is that most of the time we really do not know what is worth pursuing and what is not, and the largest single reason for this sorry state of affairs is our inadequate capacity for assessment. A complete response as currently defined leaves little to argue about except the duration, which is just as important as the "quantity" of response. We cannot, however, be so charitable about some of the criteria of partial response that have been used. Quite clearly, the minimum possible partial response criterion, a 50% volume reduction for four weeks, should be completely abandoned. A partial response assessed as a 50% area reduction for four weeks is of dubious merit, and even a 50% diameter reduction for four weeks must often be a less-than-adequate criterion, not because of the size change but owing to the pitifully short duration. This period is simply not long enough to gain any meaningful data on human tumours, particularly as the doubling times may vary from 10 to more than 160 days,7 and we have virtually no reliable data on regression rates during or after treatment.
Recently, a less-than-partial response category has been introduced to describe the responses to interferon of patients with myeloma, breast cancer, and lymphoma."3 14 In these studies the responses of the patients with breast cancer and lymphoma were assessed as the product of two diameters, which complies admirably with the UICC recommendations. This is synonymous with an area assessment, and in this context the less-than-partial response criterion is met by an area reduction of between 25-50%, which is equivalent to a mean diameter decrease of only 13-29%. As have been based on scientific observation-the burning piece of paper obviously "gives something off" and the weight of the ash is less than that of the paper before it was burnt. But the wrong conclusions were drawn, mainly owing to inability to measure the weight of the effluent gases. The analogy between the concepts of phlogiston and partial response seems to be uncomfortably close at times, and we are in real danger of drawing incorrect conclusions from the way the latter now tends to be abused. Hence the concept it should be dispatched along with that of phlogiston.
Although we do not have anything specific to measure, we could use what we have to better advantage. Firstly, the application of plastic strips with radio-opaque divisions set at one centimetre intervals placed on the front and back of every patient having a chest x-ray examination to assess tumour "size" would enable us to be sure that any changes occurring were real and not artifactual, as magnification factors could be taken into account on a routine basis. Secondly, it would be an advantage, and would probably not be too difficult to arrange, to have each patient's radiographs taken on the same machine with the same settings at each visit. Finally, and most importantly, time could be incorporated into the response criterion just as size is at present. At each visit the patient would be assessed according to the UICC recommendations, the product of two diameters being recorded. As an addition, however, the area under the response curve would be recorded to give the "cumulative response index" as the assessment criterion. This is illustrated in the figure, which shows such response curves of two hypothetical patients. In the top panel we see the percentage response at each weekly visit (hypothetical interval). Each of these patients would qualify as showing a partial response on the present criteria. The bottom panel, however, which shows the cumulative response index (obtained by summing the past and present response levels) shows clearly that the quality of response in patient A (so far as the tumour is concerned) is much better than in patient B. As long as the cumulative response index is increasing a therapeutic "gain" has been achieved. An increase in slope indicates an increase in response and a constant slope indicates that a given percentage response is being maintained. A decrease in slope while this remains positive indicates a decrease in response. No change in the cumulative response index shows that the tumour has regrown to its pretreatment size. This is illustrated between 10 and 11 weeks in patient B. A negative slope of the cumulative response index curve shows that the tumour has increased in size beyond its pretreatment value. If this system were to be adopted, and cumulative response index curves were to be published, the reader could much more easily assess the quality of response. Furthermore, frequency distributions of the cumulative response index at given times after treatment started could also be constructed. This would be achieved by "slicing" the cumulative response index data set vertically, which would give frequency versus cumulative response level at that time. We could then discard the arbitrary criteria for complete, partial, and less-thanpartial response and submit the frequency distributions to statistical analysis and follow changes in the distributions with time. We might then get nearer to discovering the truth about what we are doing or trying to do.
The use of chemotherapy in the more common tumours will gain general acceptance among the more traditional oncologists only when better and more stringent, not worse and less stringent, criteria for assessment are used by the devotees of the art. Until then non-committed surgical and radiotherapeutic oncologists will remain cynically uncommitted.
